Literature DB >> 25196788

Design and evaluation of a novel trifluorinated imaging agent for assessment of bile acid transport using fluorine magnetic resonance imaging.

Diana Vivian1, Kunrong Cheng2, Sandeep Khurana2, Su Xu3, Paul A Dawson4, Jean-Pierre Raufman5, James E Polli6.   

Abstract

Previously, we developed a trifluorinated bile acid, CA-lys-TFA, with the objective of noninvasively assessing bile acid transport in vivo using (19) F magnetic resonance imaging (MRI). CA-lys-TFA was successfully imaged in the mouse gallbladder, but was susceptible to deconjugation in vitro by choloylglycine hydrolase (CGH), a bacterial bile acid deconjugating enzyme found in the terminal ileum and colon. The objective of the present study was to develop a novel trifluorinated bile acid resistant to deconjugation by CGH. CA-sar-TFMA was designed, synthesized, and tested for in vitro transport properties, stability, imaging properties, and its ability to differentially accumulate in the gallbladders of normal mice, compared with mice with known impaired bile acid transport (deficient in the apical sodium-dependent bile acid transporter, ASBT). CA-sar-TFMA was a potent inhibitor and substrate of ASBT and the Na(+) /taurocholate cotransporting polypeptide. Stability was favorable in all conditions tested, including the presence of CGH. CA-sar-TFMA was successfully imaged and accumulated at 16.1-fold higher concentrations in gallbladders from wild-type mice compared with those from Asbt-deficient mice. Our results support the potential of using MRI with CA-sar-TFMA as a noninvasive method to assess bile acid transport in vivo.
© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  bile acid malabsorption; bile acid transporters; biliary excretion; enterohepatic circulation; fluorine MRI; imaging methods; intestinal absorption; site-specific delivery; targeted drug delivery; transporters

Mesh:

Substances:

Year:  2014        PMID: 25196788      PMCID: PMC4206604          DOI: 10.1002/jps.24131

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  39 in total

1.  Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects.

Authors:  Maria Vertzoni; Nikoletta Fotaki; Edmund Kostewicz; Erika Stippler; Christian Leuner; Eleftheria Nicolaides; Jennifer Dressman; Christos Reppas
Journal:  J Pharm Pharmacol       Date:  2004-04       Impact factor: 3.765

Review 2.  19F: a versatile reporter for non-invasive physiology and pharmacology using magnetic resonance.

Authors:  Jian-xin Yu; Vikram D Kodibagkar; Weina Cui; Ralph P Mason
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

3.  Rapid screening of increased bile acid deconjugation and bile acid malabsorption by means of the glycine-l-(14C) cholylglycine assay.

Authors:  L Pedersen; T Arnfred; E H Thaysen
Journal:  Scand J Gastroenterol       Date:  1973       Impact factor: 2.423

4.  Bile acid replacement therapy with cholylsarcosine for short-bowel syndrome.

Authors:  S Heydorn; P B Jeppesen; P B Mortensen
Journal:  Scand J Gastroenterol       Date:  1999-08       Impact factor: 2.423

5.  Bile acid malabsorption in persistent diarrhoea.

Authors:  M J Smith; P Cherian; G S Raju; B F Dawson; S Mahon; K D Bardhan
Journal:  J R Coll Physicians Lond       Date:  2000 Sep-Oct

Review 6.  Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome.

Authors:  L Wedlake; R A'Hern; D Russell; K Thomas; J R F Walters; H J N Andreyev
Journal:  Aliment Pharmacol Ther       Date:  2009-06-30       Impact factor: 8.171

7.  Enterohepatic circulation in man of a gamma-emitting bile-acid conjugate, 23-selena-25-homotaurocholic acid (SeHCAT).

Authors:  M V Merrick; M A Eastwood; J R Anderson; H M Ross
Journal:  J Nucl Med       Date:  1982-02       Impact factor: 10.057

8.  Substrate specificity of cholylglycine hydrolase for the hydrolysis of bile acid conjugates.

Authors:  A K Batta; G Salen; S Shefer
Journal:  J Biol Chem       Date:  1984-12-25       Impact factor: 5.157

9.  Description and simulation of a physiological pharmacokinetic model for the metabolism and enterohepatic circulation of bile acids in man. Cholic acid in healthy man.

Authors:  A F Hofmann; G Molino; M Milanese; G Belforte
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

10.  Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice.

Authors:  Paul A Dawson; Jamie Haywood; Ann L Craddock; Martha Wilson; Mary Tietjen; Kimberly Kluckman; Nobuyo Maeda; John S Parks
Journal:  J Biol Chem       Date:  2003-06-20       Impact factor: 5.157

View more
  5 in total

Review 1.  Intestinal Absorption of Bile Acids in Health and Disease.

Authors:  Alexander L Ticho; Pooja Malhotra; Pradeep K Dudeja; Ravinder K Gill; Waddah A Alrefai
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

2.  Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport.

Authors:  Jessica Felton; Kunrong Cheng; Anan Said; Aaron C Shang; Su Xu; Diana Vivian; Melissa Metry; James E Polli; Jean-Pierre Raufman
Journal:  J Vis Exp       Date:  2016-11-27       Impact factor: 1.355

3.  Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids.

Authors:  Jean-Pierre Raufman; Paul A Dawson; Anuradha Rao; Cinthia B Drachenberg; Jonathon Heath; Aaron C Shang; Shien Hu; Min Zhan; James E Polli; Kunrong Cheng
Journal:  Carcinogenesis       Date:  2015-07-25       Impact factor: 4.944

4.  Attenuated Accumulation of Novel Fluorine (19F)-Labeled Bile Acid Analogues in Gallbladders of Fibroblast Growth Factor-15 (FGF15)-Deficient Mice.

Authors:  Melissa Metry; Jessica Felton; Kunrong Cheng; Su Xu; Yong Ai; Fengtian Xue; Jean-Pierre Raufman; James E Polli
Journal:  Mol Pharm       Date:  2018-10-03       Impact factor: 4.939

5.  Diminished gallbladder filling, increased fecal bile acids, and promotion of colon epithelial cell proliferation and neoplasia in fibroblast growth factor 15-deficient mice.

Authors:  Kunrong Cheng; Melissa Metry; Jessica Felton; Aaron C Shang; Cinthia B Drachenberg; Su Xu; Min Zhan; Justin Schumacher; Grace L Guo; James E Polli; Jean-Pierre Raufman
Journal:  Oncotarget       Date:  2018-05-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.